Fresh Market Data
  • Investing News
  • Stock News
  • World News
  • Business News
Investing News

Elon Musk’s Neuralink raises $650 million in fresh capital

by June 3, 2025
June 3, 2025

Elon Musk’s brain tech startup Neuralink has closed a $650 million funding round, the company announced Monday.

ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, Lightspeed Venture Partners and other firms participated in the round, according to a press release. Neuralink said the fresh capital will help the company bring its technology to more patients and develop new devices that “deepen the connection between biological and artificial intelligence.”

Neuralink is building a brain-computer interface, or BCI, which is a system that translates brain signals into commands for external technologies.

The company’s first system, called Telepathy, involves 64 “threads” that are inserted directly into the brain. The threads are thinner than a human hair and record neural signals through 1,024 electrodes, according to Neuralink’s website.

The initial aim of the technology is to help patients with severe paralysis restore some independence. As of Monday, five patients have been implanted with Neuralink’s technology, and are able to “control digital and physical devices with their thoughts,” the release said.

Neuralink is currently carrying out four separate clinical trials around its Telepathy system.

BCIs have been studied in academia for decades, and several other companies, including Synchron, Paradromics and Precision Neuroscience, are developing their own systems.

Paradromics on Monday announced it successfully implanted its BCI in a human for the first time.

It’s not clear what devices Neuralink will look to develop next, but Musk has for years espoused grand ambitions for the brain tech startup. He has even claimed that he would be willing to get an implant himself.

One of the capabilities Musk has repeatedly highlighted is the ability to restore vision to blind patients.

Neuralink received a “Breakthrough Device” designation from the U.S. Food and Drug Administration for a device called Blindsight. This designation is granted to medical devices that have the potential to provide improved treatment for debilitating or life-threatening conditions.

In a post on his social media platform X in September, Musk said Blindsight will enable even those who have lost both eyes and their optic nerve to see.

Neuralink still has a long road ahead before it can commercialize these technologies.

This post appeared first on NBC NEWS
previous post
Uber delivery chief Gore-Coty is leaving after almost 13 years at ride-hailing company
next post
US Admin Fast Tracks Laramide Uranium Projects, Meta Pens Nuclear Power Deal

Related Posts

Justin Huhn: Uranium Game On — Supply “Mirage,”...

June 6, 2025

Shein and Temu see U.S. demand plunge as...

June 6, 2025

Should You Invest in Silver Bullion?

June 6, 2025

Trump Admin Strips “Safety” from AI Oversight Institute...

June 6, 2025

In-fill RC Drilling at Kamperman Confirms High-Grade Gold

June 6, 2025

Offer Booklet – Non-Renounceable Entitlement Offer

June 6, 2025

Silver Price Surges to US$36, Marking 13 Year...

June 5, 2025

Auto Industry Takes Hit as China’s Rare Earths...

June 5, 2025

Retraction of Lo Herma Scoping Study Statements

June 5, 2025

Shein and Temu see U.S. demand plunge as...

June 5, 2025

Recent Posts

  • Justin Huhn: Uranium Game On — Supply “Mirage,” De-risked Demand, Next Price Move
  • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes
  • Should You Invest in Silver Bullion?
  • Trump Admin Strips “Safety” from AI Oversight Institute in Move to Rebrand
  • In-fill RC Drilling at Kamperman Confirms High-Grade Gold

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.


    • About us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 FreshMarketData.com All Rights Reserved.

    Fresh Market Data
    • Investing News
    • Stock News
    • World News
    • Business News